

**Amendments to the Claims**

Please amend Claims 1, 3-5, 7-8 and 11-13.

Please cancel Claims 2 and 6.

The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently Amended) A method of treating psoriasis in a human comprising administering to the human an effective ~~TNF-inhibiting~~ tumor necrosis factor (TNF)-inhibiting amount of an anti-TNF antibody, wherein said anti-TNF antibody competitively inhibits binding of TNF to monoclonal antibody cA2.
2. (Canceled)
3. (Currently Amended) A method of treating psoriasis in a human comprising administering to the human an effective ~~TNF-inhibiting~~ tumor necrosis factor (TNF)-inhibiting amount of chimeric anti-TNF antibody cA2.
4. (Currently Amended) A method ~~for~~ of treating psoriasis in a human comprising administering to the human at least one monoclonal antibody cA2, or a ~~TNF tumor necrosis factor~~ binding fragment thereof.
5. (Currently Amended) A method of treating psoriasis in a human comprising administering to the human an effective ~~TNF-inhibiting~~ tumor necrosis factor (TNF)-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of TNF to monoclonal antibody cA2.

6. (Canceled)
7. (Currently Amended) A method of treating psoriasis in a human comprising administering to the human an effective ~~TNF-inhibiting~~ tumor necrosis factor (TNF)-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
8. (Currently Amended) A method of treating psoriasis in a human comprising administering to the human an effective ~~TNF-inhibiting~~ tumor necrosis factor (TNF)-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5 and an IgG1 human constant region.
9. (Original) The method of claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
10. (Original) The method of claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.: 4.
11. (Currently Amended) A method of treating psoriasis in a human comprising administering to the human an effective ~~TNF-inhibiting~~ tumor necrosis factor (TNF)-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2.

12. (Currently Amended) The method of claim 1 wherein said ~~anti-TNF~~ anti-tumor necrosis factor antibody is a humanized antibody.
13. (Currently Amended) The method of claim 1 wherein said ~~anti-TNF~~ anti-tumor necrosis factor antibody is a human antibody.